Physician profile
Rolland Rogers
NPI 1568457497
$3,328.92
in general payments reported to CMS, 2019-2025
37 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $312 · 2021: $14.01 · 2022: $153 · 2023: $503 · 2024: $559 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $580.19 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $518.92 | 2023-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $275.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $269.42 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $222.30 | 2019-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Amgen INC. | $211.89 | 2019-2025 | Evenity, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $158.90 | 2023-2025 | |
| Corcept Therapeutics | $114.63 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.54 | 2019-2024 | Jardiance |
| Pfizer INC. | $101.95 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $94.18 | 2019-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $54.22 | 2023-2024 | Rexulti, Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $53.87 | 2019 | |
| Axsome Therapeutics, INC. | $47.33 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.75 | 2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $43.01 | 2019 | |
| Allergan, INC. | $41.97 | 2020 | |
| Amarin Pharma, INC. | $34.83 | 2019 | |
| Cranial Technologies, INC | $29.85 | 2020-2025 | Doc Band |
| Optinose US, INC. | $28.88 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $25.14 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.90 | 2024 | Gvoke Hypopen |
| Dexcom, INC. | $21.13 | 2025 | Dexcom G6 Transmitter |
| Mayne Pharma Commercial LLC | $18.50 | 2023 | |
| Sanofi Pasteur INC. | $17.93 | 2020 | |
| Daiichi Sankyo INC. | $17.90 | 2023 | Injectafer |
| Glaxosmithkline, LLC. | $17.17 | 2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $16.99 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $16.92 | 2022 | |
| Currax Pharmaceuticals LLC | $16.30 | 2024 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.00 | 2025 | Xifaxan |
| Qiagen, LLC | $15.81 | 2019 | |
| Radius Health, INC. | $15.70 | 2019 | |
| Lundbeck LLC | $15.08 | 2025 | Rexulti |
| Phadia US INC. | $14.66 | 2024 | Immunocap |
| Supernus Pharmaceuticals, INC. | $13.79 | 2025 | Qelbree |
| Sanofi-Aventis U.S. LLC | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolland Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.